Lesson 6 — Limits, Risks, Reality Check

Understanding the Complex: What Is Synthetic Biology?

---

Biology is not software. This sounds obvious, but its implications are easy to underestimate.

Software, once written, doesn't change. A function that behaves correctly today will behave the same way in a year, unless someone edits it. Biological systems don't work this way. Cells evolve. Place a microorganism under pressure — say, the metabolic burden of producing a compound it has no natural reason to make — and natural selection will favor any mutation that reduces that burden. Over many generations, the engineered behavior can erode. The organism stops doing what you designed it to do, not because the DNA was changed intentionally, but because the cells that happened to carry mutations reducing the engineered function reproduced faster.

This is called evolutionary escape, and it is one of the central engineering challenges in synthetic biology. Designing systems that are robust to evolution — that either don't create selection pressure against themselves, or that include mechanisms to maintain the designed behavior — is active, difficult research.

The broader point is that the complexity of biological systems creates failure modes that have no direct analogues in mechanical or electrical engineering. Genes interact with each other. Proteins interact with each other. A change in one part of the system can have unexpected effects elsewhere — what engineers call "context dependence." The behavior of a genetic circuit depends not just on the circuit's own components but on the host cell's physiological state, which changes with growth rate, temperature, nutrient availability, and dozens of other variables.

This is why it took Keasling's team a decade to build the artemisinin pathway. Not because the design was unclear, but because the biological context kept producing surprises.

---

Biosecurity. This is the subject that most exercises policymakers, and with reason.

Synthetic biology is, by its nature, dual-use. The same techniques used to produce artemisinin or insulin can, in principle, be directed toward making harmful organisms more dangerous, or recreating dangerous organisms that no longer exist in nature. The tools are not neutral, and they are becoming more accessible.

The biosecurity community — biosecurity researchers, government agencies, international organizations — has been grappling with this for years. There are screening systems at DNA synthesis companies (before they fulfill an order, they check whether the requested sequence matches known dangerous agents). There are export controls on certain equipment. There are biosafety levels (BSL-1 through BSL-4) that regulate what kinds of experiments can be conducted in what kinds of facilities.

Whether these systems are adequate is genuinely debated. The honest answer is: for the most dangerous potential applications, probably not yet. The number of facilities capable of synthesizing long, complex DNA sequences is declining as a bottleneck, and the tools for engineering microorganisms are spreading faster than oversight frameworks. This is not a crisis — but it is a serious governance challenge that deserves sustained attention.

What this course will not do is provide specific details about particular organisms, specific vulnerabilities, or synthesis routes that could provide practical guidance toward harmful ends. The goal is to understand the general architecture of the challenge — that the same capability that cures disease can, in different hands and with different intentions, pose risks — and to think clearly about what governance responses are appropriate.

---

The bioeconomy gap. There is considerable enthusiasm — and substantial venture capital — behind the claim that synthetic biology will replace petrochemicals, transform agriculture, and decarbonize industry. The vision is compelling: instead of drilling for oil, growing feedstocks; instead of chemical synthesis, biological fermentation; microbes as the factories of the future.

The gap between this vision and current reality is significant, though it is narrowing.

Fermentation at industrial scale is expensive. The capital cost of building a fermentation facility is high. The process of optimizing a microorganism for consistent performance at scale — robustness across millions of liters of fermentation — is long. And the economics always depend on comparison: if oil is cheap, bio-based alternatives struggle. When oil prices spike, the economics improve. The bioeconomy is not inevitable; it is contingent on a combination of continued technical progress, policy support, and market conditions.

The most honest framing is probably this: synthetic biology will be a significant component of the bioeconomy in twenty years. But which specific applications succeed, at what scale, and on what timeline, is genuinely uncertain.

---

None of this invalidates the achievements described in Lesson 5. Artemisinin works. Insulin from yeast has saved millions of lives. The field is real, productive, and accelerating. The point is simply that both the enthusiasm and the concern deserve to be grounded in what the technology actually can and cannot do — not in either uncritical celebration or reflexive alarm.

The next lesson turns to the people building this field.

---

Next lesson: Who Does What? Why? Who Pays? — the institutional landscape of synthetic biology.

---

Reading time: approx. 9–10 minutes